About Half of Patients With IBD Have Zinc Deficiency

FRIDAY, Oct. 21, 2022 (HealthDay News) -- The prevalence of zinc deficiency is about 50 percent in inflammatory bowel disease (IBD) and is higher in patients with Crohn disease (CD) than those with ulcerative colitis (UC), according to a study published online Sept. 29 in Nutrients.
Roberta Zupo, from the National Institute of Gastroenterology "Saverio de Bellis" in Italy, and colleagues conducted a systematic review and meta-analysis to examine the prevalence of zinc deficiency in IBD. Nine articles met the inclusion criteria, which included 17 prevalence entries for CD and UC (nine and eight, respectively).
The researchers found that across selected studies, the prevalence of zinc deficiency showed higher values in CD than in UC. In pooled analyses, the overall mean zinc deficiency prevalence was 54 percent in the CD population compared with 41 percent in the UC population. At meta-analysis, the overall prevalence was estimated at 50 percent, with high heterogeneity (I2, 96 percent). There was no evidence of publication bias. Across selected studies, the risk for bias was moderate to low.
"The present research highlights the importance of considering zinc as a micronutrient to be monitored, because every second IBD patient shows a deficiency," the authors write. "According to our results, zinc deficiency is more prevalent in the CD population, probably due to the more severely malabsorptive nature of this condition and also in light of the proximal site of zinc absorption in the intestine."
Related Posts
Dogs Feel Grief When Canine Companion Dies
THURSDAY, Feb. 24, 2022 (HealthDay News) -- Anyone who has more than one dog...
La COVID podría vincularse con un aumento en las infecciones cerebrales en los niños
VIERNES, 5 de agosto de 2022 (HealthDay News) -- La COVID-19 podría vincularse...
Unos devastadores tornados dejan peligros a su paso: consejos para mantenerse seguro
MARTES, 4 de abril de 2023 (HealthDay News) -- Los tornados conllevan muchos...
Un panel de la FDA respalda a un controversial fármaco para la ELA en su segunda revisión, un paso raro
JUEVES, 8 de septiembre de 2022 (HealthDay News) -- El miércoles, un panel de la...
